ALK-Abelló reveals management change

29 November 2017

Denmark-based allergy specialist ALK-Abelló (ALKB: DC) today announced that Helle Skov, executive vice president of product supply and a member of ALK's board of management, leaves the company by mutual agreement.

Effective immediately, Ms Skov's areas of responsibility, which she took on when she joined ALK in October 2014, will be taken over by ALK's EVP of commercial operations, Søren Niegel, who will head up commercial operations and product supply going forward.

Carsten Hellmann, president and chief executive, said: "I would like to thank Helle for her contributions to ALK during her time with the company and I wish her the best of luck in her future career."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK